A multicenter phase II study of belotecan, a new camptothecin analogue, as a second-line therapy in patients with small cell lung cancer.
Belotecan (Camtobell, CKD602) is a new camptothecin derivative antitumor agent that belongs to the topoisomerase inhibitors. The aim of this phase II study was to evaluate the efficacy and safety of single agent belotecan as a second-line therapy in patients with small cell lung cancer (SCLC). Patients who were previously treated for SCLC were entered into the study. Belotecan was given by daily intravenous infusion for five consecutive days, every three weeks. Twenty-five patients were enrolled in this study. On an intention-to-treat basis, belotecan induced an overall response rate of 24%, a median overall survival of 9.9 months, a median time to progression of 2.2 months, and a 1-year survival rate of 38.3%. Grade 3/4 neutropenia developed in 88.0% of patients and grade 3/4 thrombocytopenia in 40.0%. Nonhematologic toxicity of grade 3 or 4 was low. The results suggest that belotecan is relatively active and well tolerated as a second-line agent in patients with SCLC.
Rhee
Chin Kook
CK
Division of Pulmonology, Department of Internal Medicine, St Mary's Hospital, The Catholic University of Korea, Republic of Korea.
Lee
Sang Haak
SH
Kim
Ju Sang
JS
Kim
Seung Joon
SJ
Kim
Seok Chan
SC
Kim
Young Kyoon
YK
Kang
Hyun Hee
HH
Yoon
Hyoung Kyu
HK
Song
Jeong Sup
JS
Moon
Hwa Sik
HS
Kim
Jin Woo
JW
Kim
Chi Hong
CH
Shim
Byoung Yong
BY
Kim
Hoon Kyo
HK
Sun
Der Sheng
DS
Kim
Kwan Hyoung
KH
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002166:Camptothecin / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D055752:Small Cell Lung Carcinoma / Q000188:drug therapy*; D016019:Survival Analysis; D059004:Topoisomerase I Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D059004:Topoisomerase I Inhibitors; C116963:belotecan; D002166:Camptothecin